#1-91E. Reassessing PTH Receptor Agonists in Osteoporosis Management (Nature Reviews Rheumatology, 2025)

In managing osteoporosis, how do we choose between the anabolic agents teriparatide and abaloparatide? This comprehensive review explores how these PTH1R agonists promote bone formation via intermittent stimulation, effectively reducing fracture risk. The core takeaway is the growing evidence from exploratory and real-world data suggesting abaloparatide may have superior efficacy in preventing non-vertebral and hip fractures compared to teriparatide. However, listeners should note this is an expert review, not definitive head-to-head trial evidence. This paper offers crucial insights for optimizing drug selection and sequencing for our highest-risk patients.Citation: FUGGLE, Nicholas, et al. Parathyroid hormone receptor agonists in the management of osteoporosis. Nature Reviews Rheumatology. 2025. DOI: 10.1038/s41584-025-01287-wDisclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original publication for detailed information.